Emerging roles of the host defense peptide LL‐37 in human cancer and its potential therapeutic applications

Citations Over TimeTop 10% of 2010 papers

Abstract

Human cathelicidin LL-37, a host defense peptide derived from leukocytes and epithelial cells, plays a crucial role in innate and adaptive immunity. Not only does LL-37 eliminate pathogenic microbes directly but also modulates host immune responses. Emerging evidence from tumor biology studies indicates that LL-37 plays a prominent and complex role in carcinogenesis. Although overexpression of LL-37 has been implicated in the development or progression of many human malignancies, including breast, ovarian and lung cancers, LL-37 suppresses tumorigenesis in gastric cancer. These data are beginning to unveil the intricate and contradictory functions of LL-37. The reasons for the tissue-specific function of LL-37 in carcinogenesis remain to be elucidated. Here, we review the relationship between LL-37, its fragments and cancer progression as well as discuss the potential therapeutic implications of targeting this peptide.

Related Papers

• → Aspects of the innate and adaptive immune responses to acute infections with BVDV(2003)58 cited
• → B Cell Functions Can Be Modulated by Antimicrobial Peptides in Rainbow Trout Oncorhynchus mykiss: Novel Insights into the Innate Nature of B Cells in Fish(2017)47 cited
• → Innate immunity and graft rejection(2000)49 cited
• → The Innate Immune System(2007)
• → Dendritic Cells (DCs) in Innate Immunity(2022)